(Total Views: 580)
Posted On: 01/29/2022 1:31:57 PM
Post# of 156518
Sorry
Dr. Kelly will speak tomorrow, November 30, 2021, at 2:55pm PST about emerging
approaches to antivirals, specifically focusing on leronlimab. Dr. Kelly’s
segment is entitled, “Leronlimab – a platform mab CCR5 antagonist and its role
in antiviral indications.”
Dr. Kelly will speak tomorrow, November 30, 2021, at 2:55pm PST about emerging
approaches to antivirals, specifically focusing on leronlimab. Dr. Kelly’s
segment is entitled, “Leronlimab – a platform mab CCR5 antagonist and its role
in antiviral indications.”
(0)
(0)
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Watchman Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Watchman Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
